53720 Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 13, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21745 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 5, 2010, 

Austin Pharma LLC., 811 Paloma Drive, 

Suite C, Round Rock, Texas 78665– 

2402, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Alphamethadol (9605) .................. I 

Nabilone (7379) ............................ II 

Methadone (9250) ........................ II 

Methadone Intermediate (9254) ... II 

Levo-alphacetylmethadol (9648) .. II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

In reference to drug code 7360 

(Marihuana), the company plans to bulk 

manufacture cannabidiol as a synthetic 

intermediate. This controlled substance 

will be further synthesized to bulk 

manufacture a synthetic THC (7370). No 

other activity for this drug code is 

authorized for this registration. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 2, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator/Deputy Chief 

of Operation, Office of Diversion Control, 

Drug Enforcement Administration. 

[FR Doc. 2010–21785 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on April 15, 2010, 

American Radiolabeled Chemicals, Inc., 

101 Arc Drive, St. Louis, Missouri 

63146, made application by renewal to 

the Drug Enforcement Administration 

(DEA) as a bulk manufacturer of the 

basic classes of controlled substances 

listed in schedules I and II: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Ibogaine (7260) ............................ I 

Lysergic acid diethylamide (7315) I 

Tetrahydrocannabinols (7370) ..... I 

Dimethyltryptamine (7435) ........... I 

1-[1-(2– 

Thienyl)cyclohexyl]piperidine 

(7470).

I 

Dihydromorphine (9145) ............... I 

Normorphine (9313) ..................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Amobarbital (2125) ....................... II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Metazocine (9240) ........................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Phenazocine (9715) ..................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

small quantities of the listed controlled 

substances as radiolabeled compounds 

for biochemical research. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 3, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21784 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 11, 2010, 

Cody Laboratories, 601 Yellowstone 

Avenue, Cody, Wyoming 82414, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Dihydromorphine (9145) ............... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Oxymorphone (9652) ................... II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans on manufacturing 

the listed controlled substances in bulk 

for sale to its customers. 


hsrobinson on DSK69SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices 53721 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 2, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21776 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 27, 2010, 

Archimica, Inc., 2460 W. Bennett Street, 

Springfield, Missouri 65807–1229, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Phenylacetone (8501) .................. II 

Methadone Intermediate (9254) ... II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 2, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21775 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 14, 2010, 

Chattem Chemicals Inc., 3801 St. Elmo 

Avenue, Building 18, Chattanooga, 

Tennessee 37409, made application by 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

4–Methoxyamphetamine (7411) ... I 

Dihydromorphine (9145) ............... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ..................... II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 2, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21773 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 4, 2010, 

Cambrex Charles City, Inc., 1205 11th 

Street, Charles City, Iowa 50616, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Phenylacetone (8501) .................. II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Dextropropoxyphene, bulk ........... II 

(non-dosage forms) (9273).

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Raw Opium (9600) ....................... II 

Opium extracts (9610) .................. II 

Opium, powdered (9639) ............. II 

Opium, granulated (9640) ............ II 

Poppy Straw (9650) ..................... II 

Oxymorphone (9652) ................... II 

Concentrate of Poppy Straw 

(9670).

II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 


hsrobinson on DSK69SOYB1PROD with NOTICES